



(51) International Patent Classification:

A61K 31/155 (2006.01) *A61P 43/00* (2006.01)*A61K 31/4375* (2006.01)

(21) International Application Number:

PCT/US2019/016161

(22) International Filing Date:

31 January 2019 (31.01.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/624,453 31 January 2018 (31.01.2018) US


(71) Applicant: **DECIPHERA PHARMACEUTICALS, LLC** [US/US]; 643 Massachusetts St., Suite 200, Lawrence, KS 66044 (US).(72) Inventors: **FLYNN, Daniel, L.**; 4165 Blackjack Oak Drive, Lawrence, KS 66047 (US). **SMITH, Bryan, D.**; 1312 Inverness Drive, Lawrence, KS 66049 (US). **GUPTA, Anu**; 1212 Chadwick Court, Lawrence, KS 66049 (US).(74) Agent: **KAVANAUGH, Theresa, C.** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMBINATION THERAPY FOR THE TREATMENT OF MASTOCYTOSIS

Figure 1A



HMC1.1 V560G



HMC1.1 V560G/D816V

(57) Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.

[Continued on next page]

Published:

— *with international search report (Art. 21(3))*